Anti Procollagen type IIA N-terminal propeptide (human, PIIANP)
Mouse monoclonal antibody
Cat.No. BTE 003-02
Preparation: Protein-A/G purified
Content: Available in 200 µL and 1 mL
Concentration: 1 mg/mL
Solvent: 0.01 M phosphate buffer, pH 7.4, with 0.5 M NaCl and 15 mM sodium azide
Storage: In the dark at 4-8ºC
Collagen type II is the most abundant protein of cartilage matrix. Two isoforms exist and collagen type IIA is involved in early development of cartilage in embryos. The collagen is produced from type II procollagen when two teloterminal propeptides are digested from the procursor and released into the circulation. Procollagen type II N-terminal propeptide (PIIANP) is considered a marker of cartilage synthesis and the normal concentration in serum is approximately 30ng/mL (1).
Recombinant expressed PIIANP
BTE 003-02 is specific for human PIIANP
Epitope is located at the amino-terminal part of procollagen type IIA
BTE 003-02 diluted in 10%FCS/TBS is well suited for immunohistochemistry on formalin-fixed, paraffin-embedded fetal tissue.
BTE 003-02 also reacts with recombinant PIIANP coated directly onto the microtiter well.
| Method | Usability | Dilution guideline | References |
| ELISA | No | ||
| Immunoblotting | Not determined | ||
| Immunohistochemistry | Yes | 1:1000 |
1. Garnero P, Ayral X, Rousseau JC, Christgau S, Sandell LJ, Dougados M, Delmas PD (2002) Uncoupling of type II collagen synthesis and degradation predicts progression of joint damage in patients with knee osteoarthritis. Arthritis Rheum 46:2613-24.
2. Zhu Y, McAlinden A, Sandell LJ. Type IIA procollagen in development of the human intervertebral disc: regulated expression of the NH(2)-propeptide by enzymic processing reveals a unique developmental pathway. Dev Dyn 220:350-62.
3. McAlinden A, Zhu Y, Sandell LJ (2001) Expression of type II procollagens during development of the human intervertebral disc. Biochem Soc Trans 30:831-8.

